Six named peptides now have a legal route into a compounding pharmacy, on a prescription, and BPC-157 is one of them. HHS says it does not intend to act against a pharmacy that compounds them. The policy was filed on October 28 and published in the Federal Register on October 30.1 It is interim, it runs while the formal 503A bulks list is still being written, and it attaches ten conditions that rule out most of what people currently buy.
One of those conditions has had almost no coverage. A qualifying product may contain only one of the six peptides, so the BPC-157 and TB-500 blends do not qualify. Our price tracking follows 126 sellers of that single preparation.2
What did HHS actually do?
HHS announced the availability of a policy document. That is a narrower action than a rule, and the Federal Register entry is a "Notice of availability" from the Office of the Secretary.1
The notice describes "the Secretary of HHS's enforcement policy regarding the use of certain peptide bulk drug substances in compounding pursuant to section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act)" and says it applies "while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act (the 503A bulks list) is developed through rulemaking."1 HHS has not replaced rulemaking. This sits on top of it while it continues.
Comments are open until two weeks after the publication date.1
Which six peptides are covered?
Appendix A covers six peptides, listed in alphabetical order: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.2 Nothing else is on it. Any peptide absent from that appendix sits exactly where it sat on October 27.
Appendix B then limits each one to particular dosage forms, and the limits are not the same across the six:
- BPC-157: "subcutaneous, intramuscular, oral, and topical dosage forms"
- TB-500 and MOTS-c: "subcutaneous or intramuscular injectable dosage forms"
- Epitalon: "subcutaneous or intramuscular injectable dosage forms that are dispensed in intermittent courses"
- KPV: "topical and oral dosage forms"
- Semax: "intranasal use"
Semax is the sharpest example. An injectable Semax preparation falls outside the policy even though Semax itself is on the list.2
Can you order these online now?
You cannot order these online under this policy. A pharmacy has to be compounding for one named patient who holds a prescription, and everything else in the FD&C Act still applies.2 Compounding under 503A means a licensed pharmacy preparing a medicine for one named patient who has a prescription for it.
Where the peptide comes from closes a second door. Whoever originally made the peptide, not a repacker and not a distributor, has to be registered with FDA and compliant with current good manufacturing practice, with its location named on the certificate of analysis, and intermediaries have to validate both the manufacturer and the certificate.2 HHS also requires the substance to come from a facility registered under section 510 of the Act, with a valid certificate of analysis whose results meet FDA's criteria.2
Read together, those three conditions describe a supply chain that the research-chemical market does not have. Our guide to vetting a vendor covers what a certificate of analysis does and does not establish. An FDA-registered CGMP manufacturer sits a long way from that, and the gap is what this policy puts between a pharmacy and a website.
Does the BPC-157 and TB-500 blend qualify?
No. The BPC-157 and TB-500 blend does not qualify. The reason is one sentence long. Condition 7 reads: "The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A."2
Both halves of that blend are on Appendix A. One vial holding both disqualifies the product anyway, and the same logic excludes any multi-peptide preparation built from the six. That covers most of the named blends people ask about. Our page for the BPC-157, TB-500 and Cartalax blend is a three-peptide example, so condition 7 rules it out twice over. No regulator had previously treated blending as a disqualifier instead of a convenience.
Scale makes that condition matter. Our price tracking for the BPC-157 and TB-500 blend follows 126 sellers, so the single most popular two-peptide preparation in the market is the one shape the policy will not cover.
What testing does the policy require?
Fifteen categories of test, named individually, each tied to a published standard. Appendix B carries a Testing Standard table that requires identity by orthogonal methods complying with ICH Q6A, assay by RP-HPLC against a reference standard under USP <621>, peptide-related impurities under ICH Q3A and USP <1503>, bacterial endotoxins by LAL under USP <85>, microbial enumeration under USP <1111>, elemental impurities by ICP-MS under USP <232> and <233>, residual solvents by GC under USP <467>, water content by Karl Fischer under USP <921>, and counter-ion content under USP <503>.2
Three entries on that table have no equivalent on a typical third-party report. Higher-order structure, aggregates and biological activity are required for peptides of eight or more amino acids, under USP <1503>. The table also calls for immunogenicity testing, by ELISA or surface plasmon resonance. Residual trifluoroacetic acid and fluoride are required, by ion chromatography and ion-selective electrode.2
Nitrosamines, thiol groups and host cell impurities appear as conditional rows, required when applicable, when cysteine is present, and for recombinantly produced peptides.2
Most research-market certificates report two things: purity by HPLC and identity by mass spectrometry. Our guide to reading a peptide COA covers what those two establish. This table asks for fifteen.
How does a pharmacy prove the peptide is what it claims?
A pharmacy has to prove the peptide's identity against Appendix B. That asks for more than a purity figure. A pharmacy has to match the peptide to the identity and route limits set out in Appendix B, including amino acid sequence, structure, molecular weight and molecular formula.2 Purity of 99% says nothing about whether the molecule in the vial is the one named on it.
The source facility has to be registered under section 510 of the Act, and its certificate of analysis has to meet FDA's criteria.2 Those are two separate tests, and a certificate from an unregistered facility satisfies neither.
Third-party reports rarely carry sequence confirmation. Mass and purity are routine on third-party reports. Nobody reports sequence identity as a matter of course, and the policy names it first.
Who exactly does the policy cover?
Three kinds of compounder are named in one sentence. HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A."2
A licensed physician appears in that list alongside pharmacies. Most coverage of this policy has described it more narrowly. What does not appear anywhere in the document is section 503B. Outsourcing facility turns up once as a phrase, inside a definition of what compounding means, and nowhere in the conditions or the enforcement sentence.2
For a clinic buying prepared vials in bulk, that difference decides everything. Outsourcing facilities supply clinics without a prescription for a named patient, 503A compounding does not work that way, and the policy addresses 503A.
Does this make BPC-157 FDA approved?
No. BPC-157 is not FDA approved. Approval is a different process from what happened here. FDA approval is a separate process, and the notice says so plainly: "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness," before it continues into manufacturing quality.1
The notice also states that the policy "does not establish any rights for any person and is not binding on HHS or the public."1 Policies that create no rights and bind nobody describe how an agency intends to use its own resources. Headlines calling this legalization are describing something the document does not claim to be.
Approval and compounding access are two different mechanisms. Approved drugs have been through an application in which FDA reviewed safety and effectiveness for a stated use. A bulk substance permitted in compounding has cleared no such review, and the pharmacy carries the responsibility for what it makes. Neither document here contains a safety or effectiveness finding about any of the six.
What about oral BPC-157?
Oral BPC-157 is on the permitted list. An oral form faces a bar that peptide products have historically failed. It requires documentation that the specific formulation achieves adequate oral bioavailability in humans.2
Specific is the word doing the work. A manufacturer cannot inherit that documentation from the molecule or from another product. Our guide to peptide capsules, nasal sprays and creams covers what has actually been measured on absorption by route. HHS is asking for the kind of evidence that coverage found thin.
KPV is the other peptide with oral among its permitted forms, so the same documentation requirement lands on it.2 Every oral product also has to clear the full testing table, because nothing in the conditions trades one requirement for another.
What does the pharmacy have to do?
The pharmacy has three obligations beyond sourcing: reporting, labeling and packaging. Three of the ten conditions cover that ground. Compounders have to report products, serious adverse events and quality problems to FDA's MedWatch program and to the relevant states, and they have to print reporting instructions on the patient labeling.2 The label has to state that the product is compounded and not for resale.2
One condition is narrower than it looks: the only delivery device that may be included with the product is a syringe cleared by FDA under 510(k).2
Over time, the reporting obligation is the part with teeth. Research-chemical sales generate no reports at all, so nothing accumulates. A compounded product under this policy generates a MedWatch trail. HHS has told itself in advance what it will do with one.
What is the 503A bulks list, and where were these six before?
Codified at 21 CFR 216.23(a), the list governs which raw ingredients a 503A pharmacy may compound with.2 The Federal Register notice describes this policy as applying "while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act (the 503A bulks list) is developed through rulemaking."1
All six spent the preceding years in Category 2. Epitalon, MOTS-c, Semax and TB-500 each "was in Category 2 from September 29, 2023, until April 22, 2026", and the BPC-157 and KPV entries record the same window from September 2023, covering both free base and acetate forms.2
Condition 1 gives the new arrangement its own name: "503A Interim Access List. The peptide bulk drug substance appears in Appendix A to this policy."2 Appendix B adds that placement in or removal from Category 2 did not itself change a peptide's status under section 503A.2
How long does this last?
Nobody knows how long it lasts. HHS calls the policy interim and names the trigger for withdrawing it. HHS "may revisit application of this interim policy (in whole or in part)" if, "among other things, a safety signal or product quality issue arises with a compounded drug product."1
The reporting obligation is the mechanism that would generate such a signal, so the policy contains both the thing that could end it and the instrument that would detect it. Because the 503A bulks list is still being developed through rulemaking, the durable question is what that rule ends up saying.1
Anyone can say something about that in the meantime. Comments run until two weeks after the 30 October publication date, under docket HHS-OASH-2026-0496.1 Whatever the rule says, it would supersede an interim policy instead of ratifying it, so a listed peptide today is not a listed peptide by default later.
What does the policy not say?
The policy does not say that any of the six is safe or effective. Neither document makes such a finding. The notice is an announcement of availability, the policy is a set of conditions under which HHS does not currently intend to act, and the sentence about establishing no rights and binding nobody is in the notice itself.1
Nothing in it addresses research-use-only sales, import, personal possession or athletic testing either. Those sit where they sat. Our guide to what research use only actually means covers that framework. This policy does not touch it.
Two further silences matter. No dose, schedule or indication appears anywhere in either document, so nothing here tells a prescriber what to prescribe these for or how much. Section 503B is absent too, leaving the outsourcing facilities that supply clinics outside everything described here.
What about peptides that are not on the list?
Nothing changed for them, and the document says nothing about them at all. Condition 1 requires the substance to appear in Appendix A, and the enforcement sentence covers compounding "using a bulk drug substance in Appendix A".2 No consequence, timeline or pathway is stated for anything else.
Six peptides out of the hundreds in circulation are on that appendix. Sermorelin, ipamorelin, CJC-1295, GHK-Cu, retatrutide, tesamorelin and everything else sit exactly where they sat on 27 October, whatever a seller's banner says this week.
Appendix A is also described as interim access, so the durable question for any peptide, listed or not, is what the rulemaking produces.1
Somebody chose these six, so a process exists that could choose others. Neither document describes it, names criteria for adding a peptide, or says whether any others are under consideration.
What did we report in July, and what changed?
Our comparison of BPC-157 and TB-500 reported the July 23 advisory committee vote recommending both for the compounding list, 8 to 6 on each, and said that a recommendation is not a decision. That part holds. I did not re-verify those vote figures at source for this piece, and they come from our own earlier coverage.
What did not hold is the timeline. That page said the FDA would decide whether to open rulemaking, publish a proposed rule, take comment and publish a final rule, and that the sequence typically runs 8 to 24 months. It also said neither compound may legally be compounded today. Three months after the vote, HHS reached the same practical result through enforcement discretion instead, without waiting for the rule. We were reasonable about the rulemaking path and wrong about the route. That page is being corrected rather than quietly updated.
Common questions
Is BPC-157 legal now?
HHS published an enforcement discretion policy on October 30 covering BPC-157 in 503A compounding, under ten conditions.1 The notice states that compounded drugs are not FDA-approved and that the policy "is not binding on HHS or the public."1
Which peptides did HHS include?
Appendix A of the policy lists six: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.2 No other peptide is covered.
Can I buy BPC-157 from a website now?
Compounding under 503A is what the policy covers, and it requires the patient-specific prescription requirement to be met.2 That describes a licensed pharmacy preparing a medicine for one named patient, not an online order.
Does the BPC-157 and TB-500 blend qualify?
No. A qualifying product may contain "only a single Active Pharmaceutical Ingredient (API)" from the list.2 A two-peptide blend fails that condition even when both peptides are listed.
Can a pharmacy compound Semax as an injection?
Appendix B covers Semax for intranasal use only.2 Each of the six has its own permitted dosage forms, and an injectable Semax preparation sits outside the policy.
Is oral BPC-157 covered?
Oral is among BPC-157's permitted forms, and condition 8 requires documentation that the specific formulation achieves adequate oral bioavailability in humans.2 It has to be for the formulation, not the molecule.
Where must the peptide come from?
The policy requires a facility registered under section 510 of the FD&C Act with a valid certificate of analysis meeting FDA's criteria, and it requires the original manufacturer, not a repacker or distributor, to be FDA-registered and CGMP-compliant with its location on the certificate.2
Does the policy cover 503B outsourcing facilities?
Section 503B does not appear in the document. The phrase "outsourcing facility" appears once, inside a definition of compounding, and not in the conditions or in the enforcement sentence.2 The policy addresses compounding under section 503A.
Can a physician compound these, or only a pharmacy?
HHS names them in one sentence: "a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A."2 A licensed physician appears alongside pharmacies.
What testing does the policy require?
Appendix B carries a table of fifteen test categories tied to published standards, including identity under ICH Q6A, assay by RP-HPLC under USP <621>, endotoxins under USP <85>, higher-order structure under USP <1503>, immunogenicity by ELISA or surface plasmon resonance, and residual trifluoroacetic acid by ion chromatography.2
Where were these six peptides before this policy?
All six were in Category 2 of the 503A bulks list, four of them from September 29, 2023 until April 22, 2026, with the BPC-157 and KPV entries recording the same window from September 2023.2
Does this change anything for other peptides?
No. Condition 1 requires the substance to appear in Appendix A, and the document states no consequence for anything not on it.2
Does this mean BPC-157 is FDA approved?
No. The Federal Register notice states that "Compounded drugs are not FDA-approved," and the policy makes no finding about safety or effectiveness.1
How long will this policy last?
HHS calls it interim and says it may revisit the policy in whole or in part if "a safety signal or product quality issue arises with a compounded drug product."1 Work on the 503A bulks list continues through rulemaking.1
Can I comment on it?
The notice opens comments until two weeks after the publication date of October 30, under docket HHS-OASH-2026-0496.1
Does this change anything about research-use-only sales?
Nothing in either document addresses research-use-only sales, import or possession. Compounding by licensed pharmacies under section 503A is what the policy covers, with the conditions attached to it.2
What has to appear on the label?
The label has to state that the product is compounded and not for resale, and reporting instructions for patients have to appear on it.2
Sources
- U.S. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register document number 2026-22192, docket HHS-OASH-2026-0496, RIN 0910-ZD94. Notice of availability, filed October 28, 2026 at 11:15 am, published October 30, 2026. Read at source via the Federal Register public inspection PDF. The federalregister.gov article page itself blocks automated retrieval, so the published HTML version was not read; the public inspection document is the same filing. Quoted for the document type, dates, docket number, the summary paragraph, the statement that compounded drugs are not FDA-approved, the statement that the policy establishes no rights and binds nobody, the comment window and the conditions for revisiting the policy.
- U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix A and Appendix B, with conditions 1 through 10. Read at source at hhs.gov. No issuance date is printed on the document; it refers to April 22, 2026 and to FDA guidance dated March 2026. Quoted for the six-peptide list, the per-peptide dosage form and route limits, and conditions 3, 4, 5, 6, 7, 8, 9 and 10 as described. Condition 7 is quoted verbatim.